Biotech Values

[biotech_researcher]

GILEAD- Outrageous gains are not limited to smaller biotech stocks. Gilead Sciences bought out Pharmasset for $11 billion to get their hands on Sovaldi, a hepatitis C drug. Gilead’s stock price has tripled in the less than three years following that acquisition with $85 billion in market value added! Sovaldi is hitting the market this year and is expected to generate $2.5 billion in sales annually. Awesome – but $85 billion in additional market cap awesome? To be clear, Gilead has tacked on the market cap of Goldman Sachs, Union Pacific or United Health Group in two-and-a-half years.

http://www.thereformedbroker.com/2014/03/23/yes-biotech-is-a-bubble-sfw/